Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GARDENIA-SLE: nipocalimab in adults with moderate-to-severe systemic lupus erythematosus
CTR20261056Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of nipocalimab in systemic lupus erythematosus (SLE), sponsored by Janssen Pharmaceutical. Started Jun 2026; status: active.
02
Drugs
nipocalimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20261056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261056.